Paid Clinical Trials Kentucky

Discover 977 paid clinical trials in Kentucky. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 977

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

Recruiting

PHASE3

Sponsor:

GB002, Inc.

Location:

Louisville, Cincinnati, Columbus, Atlantashow 47 more

Code:

NCT05934526

Conditions

Pulmonary Arterial Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Placebo

Seralutinib

Generic Dry Powder Inhaler

Primary Subtalar Arthrodesis for Calcaneal Fractures

Recruiting

Sponsor:

Wake Forest University Health Sciences

Location:

Lexington, Nashville, Greenville, Winston-Salemshow 9 more

Code:

NCT06249126

Conditions

Calcaneus Fracture

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)

Open Reduction Internal Fixation (ORIF) only

Remote Alcohol Monitoring to Facilitate Abstinence From Alcohol: Exp 1

Recruiting

Sponsor:

Mikhail N Koffarnus

Location:

Lexington, Roanoke

Code:

NCT03883126

Conditions

Alcohol Use Disorder

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Contingency management

Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice

Recruiting

EARLY_PHASE1

Sponsor:

Joshua A. Lile, Ph.D.

Location:

Lexington

Code:

NCT06312657

Conditions

Opioid Use Disorder

Eligibility Criteria

Sex: All

Age: 18 - 50

Healthy Volunteers: Not accepted

Interventions

Drug Cue

Money

Withdrawal

P200TxE Diseased Eye Image Collection

Recruiting

Sponsor:

Optos, PLC

Location:

Louisville

Code:

NCT06269666

Conditions

Retinal Disease

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Interventions

P200TxE

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting

Sponsor:

Target PharmaSolutions, Inc.

Location:

Louisville, Indianapolis, Columbus, Ashevilleshow 51 more

Code:

NCT03661866

Conditions

Atopic Dermatitis

Alopecia Areata

Hidradenitis Suppurativa

Vitiligo

Psoriasis

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Lexington, Blue Ash, Morristown, Beavercreekshow 195 more

Code:

NCT06283966

Conditions

COPD (Chronic Obstructive Pulmonary Disease)

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Interventions

BGF MDI 320/14.4/9.6 μg

GFF MDI 14.4/9.6 μg

A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Louisville, Fort Mill, Flossmoor, Rockvilleshow 8 more

Code:

NCT06450366

Conditions

Hypercholesterolemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Enlicitide Decanoate

Ezetimibe

Bempedoic Acid

Placebo for Enlicitide Decanoate

Placebo for Ezetimibe

A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Lexington, Louisville, Cincinnati, Evansvilleshow 64 more

Code:

NCT06502366

Conditions

Asthma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BDA MDI HFO 160/180 μg

BDA MDI HFA 160/180 μg

Placebo MDI HFA

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Lexington, Bardstown, Mount Sterling, Londonshow 638 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression